benzyl 2-oxo-1-{[2-(trimethylsilyl)ethoxy]methyl}-2,2',3,3'-tetrahydro-1H,1'H-spiro[1,8-naphthyridine-4,4'-pyridine]-1'-carboxylate | 885032-12-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: benzyl 2-oxo-1-{[2-(trimethylsilyl)ethoxy]methyl}-2,2',3,3'-tetrahydro-1H,1'H-spiro[1,8-naphthyridine-4,4'-pyridine]-1'-carboxylate
• 英文别名: benzyl 2'-oxo-1'-(2-trimethylsilylethoxymethyl)spiro[2,3-dihydropyridine-4,4'-3H-1,8-naphthyridine]-1-carboxylate
• CAS: 885032-12-2
• 化学式: C₂₆H₃₃N₃O₄Si
• 分子量: 479.651
• InChiKey: YJMMYAOARPDEQV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.92
• 重原子数：
  34
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  72
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  benzyl 2-oxo-1-{[2-(trimethylsilyl)ethoxy]methyl}-2,2',3,3'-tetrahydro-1H,1'H-spiro[1,8-naphthyridine-4,4'-pyridine]-1'-carboxylate 在 三氟乙酸 、 乙二胺 作用下， 以 二氯甲烷 为溶剂， 反应 21.0h， 生成 2,3-dihydro-1H,1'H-spiro[pyridine-4,4'-[1,8]naphthyridin]-2'(3'H)-one
  参考文献：
  名称：

  WO2006/99268

  摘要：

  公开号：
• 作为产物：
  描述：

  benzyl 4-[2-((3-bromopyridin-2-yl){[2-(trimethylsilyl)ethoxy]methyl}amino)-2-oxoethyl]-3,6-dihydropyridine-1(2H)-carboxylate 在 二(三叔丁基膦)钯 N-甲基二环己基胺 作用下， 以 1,4-二氧六环 为溶剂， 反应 2.08h， 生成 benzyl 2-oxo-1-{[2-(trimethylsilyl)ethoxy]methyl}-2,2',3,3'-tetrahydro-1H,1'H-spiro[1,8-naphthyridine-4,4'-pyridine]-1'-carboxylate
  参考文献：
  名称：

  [EN] CGRP RECEPTOR ANTAGONISTS
  [FR] ANTAGONISTES DU RECEPTEUR DE CGRP

  摘要：

  公开号：

  WO2006041830A3

文献信息

• Cgrp Receptor Antagonists
  申请人：Burgey S. Christopher

  公开号：US20080070899A1

  公开（公告）日：2008-03-20

  The present invention is directed to compounds of Formula I: Formula I: I and Formula II: (where variables R 1 , R 2 , R 3 , R 4 , A, B, J, Q, T, V, W, X and Y are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  本发明涉及公式I和公式II的化合物： 公式I：I 和公式II：（其中变量R1、R2、R3、R4、A、B、J、Q、T、V、W、X和Y的定义如本文所述），其作为CGRP受体拮抗剂在治疗或预防涉及CGRP的疾病方面具有用途，例如头痛、偏头痛和群集头痛。本发明还涉及包含这些化合物的制药组合物以及使用这些化合物和组合物在预防或治疗涉及CGRP的疾病方面的用途。
• Heterocyclic benzodiazepine cgrp receptor antagonists
  申请人：Williams Theresa M.

  公开号：US20090105228A1

  公开（公告）日：2009-04-23

  Compounds of formula I: (where variables R 2 , R 7 , D, W, X, Y and Z are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  公式I的化合物：（其中变量R2，R7，D，W，X，Y和Z如本文所述），它们是CGRP受体的拮抗剂，并且可用于治疗或预防与CGRP有关的疾病，如偏头痛。本发明还涉及包含这些化合物的制药组合物以及使用这些化合物和组合物预防或治疗CGRP参与的这些疾病。
• CGRP RECEPTOR ANTAGONISTS
  申请人：Burgey Christopher S.

  公开号：US20100113419A1

  公开（公告）日：2010-05-06

  The present invention is directed to compounds of Formula I: Formula I: Formula II: (where variables R 1 , R 2 , R 3 , R 4 , A, B, J, Q, T, V, W, X and Y are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  本发明涉及I式化合物：I式：II式：（其中变量R1、R2、R3、R4、A、B、J、Q、T、V、W、X和Y的定义如本文所述），用作CGRP受体拮抗剂，有助于治疗或预防CGRP参与的疾病，如头痛、偏头痛和集群头痛。本发明还涉及包含这些化合物的药物组合物以及这些化合物和组合物在预防或治疗CGRP参与的疾病方面的使用。
• CGRP receptor antagonists
  申请人：Merck Sharp & Dohme Corp.

  公开号：US07994325B2

  公开（公告）日：2011-08-09

  Compounds of Formula I: (where variables R1, A, B, W, X, Y and Z are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  化合物公式I：（其中变量R1，A，B，W，X，Y和Z的定义如下）是CGRP受体拮抗剂，可用于治疗或预防CGRP参与的疾病，例如头痛，偏头痛和集群头痛。本发明还涉及包含这些化合物的制药组合物以及这些化合物和组合物在预防或治疗CGRP参与的这些疾病中的使用。
• Heterocyclic benzodiazepine CGRP receptor antagonists
  申请人：Merck Sharp & Dohme Corp.

  公开号：US07947678B2

  公开（公告）日：2011-05-24

  Compounds of formula I: (where variables R2, R7, D, W, X, Y and Z are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  化合物I的公式：（其中变量R2、R7、D、W、X、Y和Z如本文所述），它们是CGRP受体拮抗剂，可用于治疗或预防CGRP参与的疾病，如偏头痛。本发明还涉及包含这些化合物的药物组合物以及这些化合物和组合物在预防或治疗CGRP参与的这些疾病中的使用。